Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics Inc (NQ: MRSN )

2.045 +0.005 (+0.25%)
Streaming Delayed Price Updated: 11:10 AM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mersana Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug
Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The... 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Mersana Therapeutics Q1 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2... 
Via Benzinga
Looking Into Mersana Therapeutics's Return On Capital Employed
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in... 
Via Benzinga
Recap: Mersana Therapeutics Q4 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI)... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
78 Biggest Movers From Friday
Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced a  
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 338.2% to $2.82 during Thursday's pre-market session. The market value of their outstanding shares is at $284.5... 
Via Benzinga
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B
Synaffix B.V. has expanded its license agreement with Mersana Therapeutics Inc (NASDAQ: MRSN) for antibody-drug conjugates (ADCs) targeting cancers. The... 
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 11.17%, resulting in... 
Via Benzinga
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.